Dataset Information

Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training: a randomised controlled trial.

ABSTRACT:

Introduction

Many athletes use short-acting inhaled β₂-agonists multiple times weekly during training sessions to prevent exercise-induced bronchoconstriction, but it is unclear if treatment impairs training outcomes. Herein, we investigated performance adaptations in well-trained females and males training with prior inhalation of salbutamol.

Methods

19 females and 21 males with maximal oxygen uptake (V'_{O_2max}) of 50.5±3.3 and 57.9±4.9 mL·min^-1·kg^-1, respectively, participated in this double-blinded, placebo-controlled, parallel-group study. We randomised participants to placebo or salbutamol inhalation (800-1600 µg·training day^-1) for 6 weeks of combined endurance (1× per week) and high-intensity interval training (2× per week). We assessed participants' body composition, V'_{O_2max} and muscle contractile function, and collected vastus lateralis muscle biopsies.

Results

Salbutamol induced a sex-specific loss of whole-body fat mass (sex×treatment: p=0.048) where only salbutamol-treated females had a fat mass reduction compared to placebo (-0.8 kg at 6 weeks; 95% CI: -0.5 to -1.6; p=0.039). Furthermore, salbutamol-treated females exhibited a repartitioning effect, lowering fat mass while gaining lean mass (p=0.011), which was not apparent for males (p=0.303). Salbutamol negatively impacted V'_{O_2max} in both sexes (treatment main effect: p=0.014) due to a blunted increase in V'_{O_2max} during the initial 4 weeks of the intervention. Quadriceps contractile strength was impaired in salbutamol-treated females (-39 N·m; 95% CI: -61 to -17; p=0.002) compared to placebo at 6 weeks. Muscle electron transport chain complex I-V abundance increased with salbutamol (treatment main effect: p=0.035), while content of SERCAI, β₂-adrenoceptor and desmin remained unchanged.

Conclusion

Inhaled salbutamol appears to be an effective repartitioning agent in females but may impair aerobic and strength-related training outcomes.

SUBMITTER: Hostrup M

PROVIDER: S-EPMC10752270 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training: a randomised controlled trial.

Hostrup Morten M Weinreich Cecilie C Bjerre Mathias M Kohlbrenner Dario D Bangsbo Jens J Jessen Søren S

ERJ open research 20231101 6

<h4>Introduction</h4>Many athletes use short-acting inhaled β<sub>2</sub>-agonists multiple times weekly during training sessions to prevent exercise-induced bronchoconstriction, but it is unclear if treatment impairs training outcomes. Herein, we investigated performance adaptations in well-trained females and males training with prior inhalation of salbutamol.<h4>Methods</h4>19 females and 21 males with maximal oxygen uptake (<i>V</i>'<sub>O<sub>2max</sub></sub>) of 50.5±3.3 and 57.9±4.9 mL·mi ...[more]

PMID: 38152086

Similar Datasets

Project description:PurposeThis study examined the effects of repeated long-duration hyperoxic water immersions (WIs) at 1.35 atmospheres absolute (ATA) on neuromuscular endurance performance. We hypothesized that over a 5-day period of consecutive, resting, long-duration hyperoxic WIs there would be a decrease to neuromuscular endurance performance and tissue oxygenation with the quadriceps muscle, but not with the forearm flexors.MethodsThirteen well-trained, male subjects completed five consecutive 6-h resting WIs with 18-h surface intervals during the dive week while breathing 100% oxygen at 1.35 ATA. We assessed skeletal muscle endurance performance before and after each WI, and 24 and 72 h after the final WI. Muscular endurance assessments included 40% maximal handgrip endurance (MHE) and 50-repetition maximal isokinetic (IK) knee extensions. Near-infrared spectroscopy (NIRS) was used to measure muscle oxidative capacity (MOC) of the vastus lateralis and localized muscle tissue oxygenation of the vastus lateralis and flexor carpi radialis. Simultaneously, we measured brachioradialis neuromuscular activation by surface electromyography (SEMG).ResultsMHE time-to-fatigue performance declined by 15% at WI 3 (p = 0.009) and by 17% on WI 5 (p = 0.002). Performance continued to decline by 22% at 24-h post-WI (p < 0.001) and by 12% on 72-h post-WI (p = 0.019). Fifty-repetition IK knee extension total work decreased by 5% (p = 0.002) on WI 3, and was further reduced by 7.5 and 12.3% (p = 0.032) at pre-WI 5 and 24-h post-WI, respectively. However, the rate of fatigue was 8 (p = 0.033) and 30% (p = 0.017) lower at WI 3 and 24-h post-WI when compared to WI 1, respectively, demonstrating the muscles were still fatigued from the previous hyperoxic WIs. We detected no significant limitations in oxygen off-loading kinetics during the exercise or MOC measurements.ConclusionRepeated, resting, long-duration hyperoxic WIs caused significant reductions to muscular endurance but not to indirect measures of oxygen kinetics in load bearing and non-load bearing muscles.

Project description:BackgroundThe 2022 Global Initiative for Asthma guidelines emphasise the inhaled long-acting β2-agonist formoterol as part of the first treatment step, and therefore formoterol use among athletes will probably increase. However, prolonged supratherapeutic use of inhaled β2-agonists impairs training outcomes in moderately trained men. We investigated whether inhaled formoterol, at therapeutic doses, imposes detrimental effects in endurance-trained individuals of both sexes.Methods51 endurance-trained participants (31 male, 20 female; mean±sd maximal oxygen consumption (V̇ O2 max) 62±6 mL·min-1·kg bw-1 and 52±5 mL·min-1·kg bw-1, respectively) inhaled formoterol (24 µg; n=26) or placebo (n=25) twice daily for 6 weeks. At baseline and follow-up, we assessed V̇ O2 max and incremental exercise performance during a bike-ergometer ramp-test; body composition by dual-energy X-ray absorptiometry; muscle oxidative capacity by high-resolution mitochondrial respirometry, enzymatic activity assays and immunoblotting; intravascular volumes by carbon monoxide rebreathing; and cardiac left ventricle mass and function by echocardiography.ResultsCompared to placebo, formoterol increased lean body mass by 0.7 kg (95% CI 0.2-1.2 kg; treatment×trial p=0.022), but decreased V̇ O2 max by 5% (treatment×trial p=0.013) and incremental exercise performance by 3% (treatment×trial p<0.001). In addition, formoterol lowered muscle citrate synthase activity by 15% (treatment×trial p=0.063), mitochondrial complex II and III content (treatment×trial p=0.028 and p=0.007, respectively), and maximal mitochondrial respiration through complexes I and I+II by 14% and 16% (treatment×trial p=0.044 and p=0.017, respectively). No apparent changes were observed in cardiac parameters and intravascular blood volumes. All effects were sex-independent.ConclusionOur findings demonstrate that inhaled therapeutic doses of formoterol impair aerobic exercise capacity in endurance-trained individuals, which is in part related to impaired muscle mitochondrial oxidative capacity. Thus, if low-dose formoterol fails to control respiratory symptoms in asthmatic athletes, physicians may consider alternative treatment options.

Project description:BackgroundCitrulline may amplify the effects of L-arginine and nitric oxide concentration, which may augment vasodilation and blood flow, thereby enhancing aerobic exercise performance. The purpose of this randomized, double-blind, placebo-controlled crossover study was to investigate effects of L-citrulline + Glutathione on aerobic exercise performance and blood flow in well-trained men.MethodsTwenty-five males (Mean ± SD; Age: 22.2 ± 2.4 yrs; Height: 177.0 ± 4.8 cm; Weight: 75.3 ± 6.9 kg) were randomly assigned to the L-citrulline + Glutathione (Setria Performance Blend: SPB; L-citrulline [2 g] + glutathione [200 mg], 6 capsules) or placebo (PL; 3.1 g cellulose, 6 capsules) group. Participants performed a maximal oxygen consumption treadmill test to determine peak velocity (PV) and returned after eight days of ingesting either PL or SPB. Three timed treadmill runs to exhaustion (TTE) were performed at 90%, 100%, and 110% PV. Brachial artery blood flow and vessel diameter were assessed using ultrasound at 1-hr prior to exercise (1hrPrEX), after each exercise bout, immediately post-exercise (immediate PEX), and 30 minutes post exercise (30minPEX) at visits 2 and 4. Blood analytes were assessed via venous blood draws at visit 1, visit 3, and 1hrPEX, immediate PEX, and 30minPEX at visits 2 and 4. After a 14-day washout, participants repeated the same procedures, ingesting the opposite treatment. Separate repeated measures ANOVAs were performed for TTE, vessel diameter, blood flow, and blood analytes.ResultsBlood flow was significantly augmented 30minPEX (p = 0.04) with SPB in comparison with PL. L-citrulline and L-arginine plasma concentrations were significantly elevated immediately PEX (p = 0.001) and 30-minPEX (p = 0.001) following SPB in comparison to PL.ConclusionAcute ingestion of SPB after eight days may enhance blood flow, L-citrulline, and L-arginine plasma concentrations after high-intensity exercise, which may enhance performance.Clinical trial registration[https://clinicaltrials.gov/ct2/show/nct04090138], identifier [NCT04090138].

Dataset Information

Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training: a randomised controlled trial.

Introduction

Methods

Results

Conclusion

Publications

Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training: a randomised controlled trial.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets